Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 11/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.40 |
| ▸ | CDK2 | P24941 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EBP | Q15125 | 2/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6024368 | 0.94 | PDE2A (0.46) | PDE2APOLBCCNE2CDK4CCND1 | |
| SCHEMBL6024717 | 0.94 | PDE2A (0.46) | PDE2APOLBCCNE2CDK4CCND1 | |
| SCHEMBL7442320 | 0.87 | PDE2A (0.52) | PDE2ACCNE2CCNE1CDK2ALDH1A1 | |
| SCHEMBL6023455 | 0.86 | PDE2A (0.43) | PDE2ACCNE2CDK4CCND1CCNE1 | |
| SCHEMBL6023491 | 0.86 | PDE2A (0.44) | PDE2ARNASEH1 | |
| SCHEMBL6024017 | 0.84 | PDE2A (0.41) | PDE2APOLBALDH1A1TP53RNASEH1 | |
| SCHEMBL6992393 | 0.82 | PDE2A (0.55) | PDE2APOLBCCNE2CDK4CCND1 | |
| SCHEMBL6023204 | 0.82 | PDE2A (0.51) | PDE2ARNASEH1 | |
| SCHEMBL6023837 | 0.82 | PDE2A (0.51) | PDE2ARNASEH1 | |
| SCHEMBL6024621 | 0.81 | PDE2A (0.36) | PDE2APOLBALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059335-A1 | METHODS OF TREATING AGE-RELATED AND INHERITED RETINAL DYSFUNCTIONS | UNIVERSITY OF CALIFORNIA - IRVINE (US) | 2024-03-21 | — | — | WO | claimed |
| WO-2024035435-A1 | DRUG-COATED MEDICAL DEVICES AND METHODS OF MAKING | BARD PERIPHERAL VASCULAR, INC. (US) | 2024-02-15 | — | — | WO | claimed |
| WO-2023012244-A1 | COMBINATION THERAPY | JAZ Innovation Limited (GB) | 2023-02-09 | — | — | WO | claimed |
| US-20220218630-A1 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | JENIVISION INC. | 2022-07-14 | — | — | US | claimed |
| CN-113993511-A | Methods and formulations for treating visual disorders | 杰尼视界公司 | 2022-01-28 | — | — | CN | claimed |
| US-20210393639-A1 | VASOACTIVE TOPICAL COMPOUND TO AFFECT TISSUE BLOOD FLOW, REDUCE TISSUE NECROSIS AND PROMOTE HEALING | SOUTH DAKOTA BOARD OF REGENTS | 2021-12-23 | — | — | US | claimed |
| US-20210330736-A1 | USE OF A PDE11 OR PDE2 INHIBITOR FOR THE TREATMENT OF PARKINSON'S DISEASE | UNIVERSITEIT VAN AMSTERDAM (NL) | 2021-10-28 | — | — | US | claimed |
| EP-3846788-A1 | USE OF A PDE11 OR PDE2 INHIBITOR FOR THE TREATMENT OF PARKINSON'S DISEASE | Universiteit van Amsterdam (NL) | 2021-07-14 | — | — | EP | claimed |
| CN-112996492-A | Use of PDE11 or PDE2 inhibitors for the treatment of Parkinson's disease | 阿姆斯特丹大学 | 2021-06-18 | — | — | CN | claimed |
| WO-2020185674-A1 | A VASOACTIVE TOPICAL COMPOUND TO AFFECT TISSUE BLOOD FLOW, REDUCE TISSUE NECROSIS AND PROMOTE HEALING | SOUTH DAKOTA BOARD OF REGENTS (US) | 2020-09-17 | — | — | WO | claimed |
| EP-3013352-B1 | MECHANISM AND DRUG TARGETS FOR REDUCING CELL EDEMA (NEUROPROTECTION) AND CYTOPLASMIC EXCITABILITY IN ASTROCYTES IN NORMAL AND PATHOLOGICAL STATES | CELICA BIOMEDICAL (SI) | 2018-09-05 | — | — | EP | claimed |
| US-20160139112-A1 | MECHANISM AND DRUG TARGETS FOR REDUCING CELL EDEMA (NEUROPROTECTION) AND CYTOPLASMIC EXCITABILITY IN ASTROCYTES IN NORMAL AND PATHOLOGICAL STATES | CELICA BIOMEDICAL (SI) | 2016-05-19 | — | — | US | claimed |
| EP-3013352-A1 | MECHANISM AND DRUG TARGETS FOR REDUCING CELL EDEMA (NEUROPROTECTION) AND CYTOPLASMIC EXCITABILITY IN ASTROCYTES IN NORMAL AND PATHOLOGICAL STATES | Celica BIOMEDICAL (SI) | 2016-05-04 | — | — | EP | claimed |
| WO-2014206948-A1 | MECHANISM AND DRUG TARGETS FOR REDUCING CELL EDEMA (NEUROPROTECTION) AND CYTOPLASMIC EXCITABILITY IN ASTROCYTES IN NORMAL AND PATHOLOGICAL STATES | CELICA D.O.O. (SI) | 2014-12-31 | — | — | WO | claimed |
| EP-2818177-A1 | Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states | Celica, D.O.O. (SI) | 2014-12-31 | — | — | EP | claimed |
| US-20060229242-A1 | Composition comprising a pulmonary surfactant and a pde2 inhibitor | ALTANA PHAZMA AG (DE) | 2006-10-12 | — | — | US | claimed |
| EP-1660132-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA Pharma AG (DE) | 2006-05-31 | — | — | EP | claimed |
| WO-2005021037-A1 | COMPOSITION COMPRISING A PULMONARY SURFACTANT AND A PDE2 INHIBITOR | ALTANA PHARMA AG (DE) | 2005-03-10 | — | — | WO | claimed |
| EP-3870300-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AS PDE2 INHIBITORS | INTRA CELLULAR THERAPIES INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-1097707-A1 | Treatment of female sexual dysfunction | Pfizer Limited (GB) | 2001-05-09 | — | — | EP | disclosed |